SecurityGPAC / Global Partner Acquisition Corp. (37954X105)
Institutional Owners8
Institutional Shares60,121,412 - 136.42%
Institutional Value$ 13,520,000 USD

Institutional Stock Ownership and Shareholders

Global Partner Acquisition Corp. (NASDAQ:GPAC) has 8 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 60,121,412 shares. Largest shareholders include Innohold, Llc, Coliseum Capital Management, LLC, Global Partner Sponsor I LLC, Davidson Kempner Partners, Highbridge Capital Management Llc, Baleen Capital Management Llc, Greenhaven Road Capital Fund 1, and Morgan Stanley.
Global Partner Acquisition Corp. (NASDAQ:GPAC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-02-14 13F-HR MORGAN STANLEY 1 0
2018-02-14 13F-HR UBS Group AG 78 0 -100.00 1 0 -100.00
2018-05-15 13F-HR Polar Asset Management Partners Inc. 1,596,794 0 -100.00 15,992 0 -100.00
2018-05-07 13F-HR Periscope Capital Inc. 181,800 0 -100.00 1,827 0 -100.00
2018-05-15 13F-HR BASSO CAPITAL MANAGEMENT, L.P. 441,762 0 -100.00 4,418 0 -100.00
2018-02-27 SC 13D Innohold, Llc 44,071,318
2018-02-14 13F-HR HIGHBRIDGE CAPITAL MANAGEMENT LLC 1,350,000 1,350,000 0.00 13,554 13,520 -0.25
2018-05-15 13F-HR BERKLEY W R CORP 406,445 0 -100.00 4,085 0 -100.00
2018-02-12 SC 13D Coliseum Capital Management, LLC 8,184,999
2018-05-11 13F-HR TD ASSET MANAGEMENT INC 1,213,700 0 -100.00 12,137 0 -100.00
2018-01-24 13F-HR MIZUHO SECURITIES USA INC. 104,381 0 -100.00 1,047 0 -100.00
2018-05-15 13F-HR Moore Capital Management, LP 600,000 0 -100.00 6,000 0 -100.00
2018-05-15 13F-HR CAPSTONE INVESTMENT ADVISORS, LLC 515,300 0 -100.00 5,178 0 -100.00
2018-03-29 13F-HR/A Marshall Wace LLP 200,000 0 -100.00 2,000 0 -100.00
2018-05-04 13F-HR VERTEX ONE ASSET MANAGEMENT INC. 56,100 0 -100.00 561 0 -100.00
2018-05-11 13F-HR GLAZER CAPITAL, LLC 365,716 0 -100.00 3,675 0 -100.00
2018-02-07 SC 13G Greenhaven Road Capital Fund 1 800,000
2018-05-15 13F-HR DEUTSCHE BANK AG\ 839,661 0 -100.00 8,438 0 -100.00
2018-05-16 13F-HR/A COWEN GROUP, INC. 434,183 0 -100.00 4,364 0 -100.00
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 79,559 0 -100.00 797 0 -100.00
2018-05-15 13F-HR Davidson Kempner Capital Management LP 1,435,094 0 -100.00 14,322 0 -100.00
2018-02-12 SC 13G/A DAVIDSON KEMPNER PARTNERS 1,435,094
2018-02-16 SC 13G Baleen Capital Management Llc 1,345,000
2018-02-13 SC 13D Global Partner Sponsor I LLC 3,881,250 2,935,000 -24.38
2018-05-15 13F-HR ARROWGRASS CAPITAL PARTNERS (US) LP 963,800 0 -100.00 9,686 0 -100.00
2018-05-11 13F-HR Amtrust Financial Services, Inc. 300,000 0 -100.00 3,000 0 -100.00

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Purple Innovation's (PRPL) CEO Terry Pearce on Q1 2018 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Greetings, ladies and gentlemen, and welcome to Purple Innovation First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] (10-1)

Purple Innovation's (PRPL) Q4 2017 Results - Earnings Call Transcript

2018-03-16 seekingalpha
Purple Innovation, Inc. (NASDAQ:PRPL) Q4 2017 Results Earnings Conference Call March 15, 2018 4:30 PM ET (7-2)

Purple Is The New Green - An Asymmetric Investment Opportunity

2018-02-14 seekingalpha
Purple represents a best-of-breed, bed-in-a-box, direct-to-consumer mattress supplier, enjoying explosive growth due to a differentiated product and viral digital marketing. (55-4)

BRIEF-Global Partner Acquisition And Purple Innovation Announces Definitive Agreement

2018-01-30 reuters

CUSIP: 37954X105